Supplementary table 3. USF1 SNPs and haplotypes and their association with SP type and NFT prevalence (APOE4 carriership and age as covariates) in females.

	rs10908821				rs2073658				rs2774276				rs2516839				rs1556259				rs2774279			
	Aff. (%) CC*/G+	OR	CI	*p*	Aff. (%) CC*/T+	OR	CI	*p*	Aff. (%) CC*/G+	OR	CI	*p*	Aff. (%) TT*/C+	OR	CI	*p*	Aff. (%) AA*/G+	OR	CI	*p*	Aff. (%) CC*/T+	OR	CI	*p*
SP	59(39.1)/23(52.3)	2.95	1.25-6.96	0.014	35(41.7)/47(42.0)	1.03	0.53-2.00	NS	46(41.1)/36(42.4)	1.32	0.68-2.57	NS	33(40.2)/49(43.4)	1.36	0.70-2.66	NS	65(42.2)/16(39.0)	0.96	0.42-2.20	NS	43(41.7)/39(42.9)	0.98	0.51-1.90	NS
Non neuritic	19(12.8)/4(9.3)	1.20	0.35-4.07	NS	8(9.9)/15(13.4)	1.41	0.54-3.65	NS	16(14.4)/7(8.4)	0.64	0.24-1.69	NS	12(14.8)/11(9.9)	0.70	0.28-1.75	NS	18(11.9)/5(12.2)	0.98	0.33-2.96	NS	12(11.7)/11(12.5)	1.10	0.44-2.75	NS
Neuritic	35(23.5)/16(37.2)	3.27	1.29-8.29	0.013	22(27.2)/29(25.9)	0.96	0.45-2.05	NS	27(24.3)/24(28.9)	1.59	0.74-3.43	NS	20(24.7)/31(27.9)	1.30	0.60-2.82	NS	41(27.2)/9(22.0)	0.73	0.28-1.94	NS	27(26.2)/24(27.3)	1.04	0.49-2.22	NS
Diffuse	5(3.4)/2(4.7)	2.33	0.40-13.6	NS	4(4.9)/3(2.7)	0.55	0.12-2.58	NS	3(2.7)/4(4.8)	1.95	0.41-9.27	NS	2(2.5)/5(4.5)	1.92	0.36-10.4	NS	5(3.3)/2(4.9)	1.39	0.25-7.69	NS	3(2.9)/4(4.5)	1.63	0.35-7.70	NS
Primitive	14(9.4)/2(4.7)	0.83	0.17-4.09	NS	4(4.9)/12(10.7)	2.28	0.68-7.63	NS	13(11.7)/3(3.6)	0.34	0.09-1.28	NS	10(12.3)/6(5.4)	0.47	0.16-1.39	NS	13(8.6)/3(7.3)	0.82	0.21-2.04	NS	9(8.7)/7(8.0)	0.92	0.32-2.69	NS
Classic	30(20.1)/10(23.3)	2.50	0.92-6.77	NS	16(19.8)/24(21.4)	1.07	0.48-2.40	NS	24(21.6)/16(19.3)	1.22	0.54-2.75	NS	21(18.9)/1(1.2)	0.97	0.44-2.17	NS	33(21.9)/7(17.1)	0.73	0.26-2.04	NS	20(19.4)/20(22.7)	1.13	0.51-2.51	NS
Burnt out	5(3.4)/6(14.0)	10.8	2.34-49.7	0.002	6(7.4)/5(4.5)	0.59	0.15-2.33	NS	3(2.7)/8(9.6)	6.56	1.36-31.5	0.019	1(1.2)/10(9.0)	9.20	1.04-81.6	0.046	8(5.3)/2(4.9)	0.66	0.11-3.98	NS	7(6.8)/4(4.5)	0.73	0.18-2.94	NS
Cerad ≤1.5%	24(15.9)/11(25.0)	3.20	1.20-8.51	0.020	17(20.2)/18(16.1)	0.84	0.38-1.89	NS	20(17.9)/15(17.6)	1.19	0.53-2.70	NS	15(18.3)/20(17.7)	1.18	0.52-2.66	NS	28(18.2)/6(14.6)	0.85	0.30-2.43	NS	16(15.5)/19(20.9)	1.29	0.58-2.90	NS
Cerad >1.5%	35(23.2)/12(27.3)	2.66	0.98-7.22	0.055	18(21.4)/29(25.9)	1.24	0.56-2.75	NS	26(23.2)/21(24.7)	1.47	0.67-3.26	NS	18(22.0)/29(25.7)	1.57	0.70-3.49	NS	37(24.0)/10(24.4)	1.05	0.39-2.78	NS	27(26.2)/20(22.0)	0.77	0.35-1.70	NS
NFT	71(55.5)/18(51.4)	0.95	0.39-2.32	NS	34(50.0)/55(57.3)	1.38	0.67-2.86	NS	53(57.0)/37(51.4)	0.80	0.39-1.63	NS	39(56.5)/50(53.2)	0.88	0.43-1.81	NS	71(55.5)/17(48.6)	0.81	0.34-1.94	NS	52(57.8)/37(51.4)	0.78	0.38-1.60	NS

	Haplotype 2 (CCCTAT)				Haplotype 3 (CCCCGC)				Haplotype 4 (CCGCAC)				Haplotype 5 (CTCTAC)				Haplotype 7 (GCGCAC)			
	Aff. (%) H2-*/H2+	OR	CI	*p*	Aff. (%) H3-*/H3+	OR	CI	*p*	Aff. (%) H4-*/H4+	OR	CI	*p*	Aff. (%) H5-*/H5+	OR	CI	*p*	Aff. (%) H7-*/H7+	OR	CI	*p*
SP	47(40.9)/39(42.4)	0.99	0.52-1.89	NS	69(41.8)/17(40.5)	1.03	0.45-2.32	NS	69(43.1)/17(36.2)	0.74	0.35-1.56	NS	35(41.7)/51(41.5)	1.01	0.53-1.94	NS	63(38.7)/23(52.3)	2.93	1.25-6.85	0.013
Non neuritic	14(11.9)/11(12.4)	1.05	0.43-2.54	NS	20(12.1)/5(11.9)	0.99	0.33-2.95	NS	21(13.0)/4(8.7)	0.53	0.17-1.69	NS	8(9.9)/17(13.5)	1.44	0.57-3.66	NS	21(12.8)/4(9.3)	1.18	0.35-3.95	NS
Neuritic	30(25.4)/24(27.0)	1.08	0.52-2.27	NS	44(26.7)/10(23.8)	0.84	0.32-2.16	NS	44(27.3)/10(21.7)	0.73	0.30-1.76	NS	22(27.2)/32(25.4)	0.92	0.43-1.94	NS	38(23.2)/16(37.2)	3.35	1.32-8.47	0.011
Diffuse	3(2.5)/4(4.5)	1.82	0.39-8.56	NS	5(3.0)/2(4.8)	1.53	0.28-8.45	NS	5(3.1)/2(4.3)	1.09	0.20-5.94	NS	4(4.9)/3(2.4)	0.49	0.10-2.29	NS	5(3.0)/2(4.7)	2.54	0.44-14.8	NS
Primitive	11(9.3)/7(7.9)	0.83	0.30-2.34	NS	15(9.1)/3(7.1)	0.80	0.21-3.06	NS	16(9.9)/2(4.3)	0.35	0.08-1.64	NS	4(4.9)/14(11.1)	2.41	0.73-7.91	NS	16(9.8)/2(4.7)	0.78	0.16-3.81	NS
Classic	23(19.5)/20(22.5)	1.13	0.52-2.47	NS	36(21.8)/7(16.7)	0.74	0.27-2.07	NS	36(22.4)/7(15.2)	0.61	0.23-1.61	NS	16(19.8)/27(21.4)	1.05	0.47-2.33	NS	33(20.1)/10(23.3)	0.52	0.93-6.83	NS
Burnt out	7(5.9)/4(4.5)	0.88	0.22-3.50	NS	8(4.8)/3(7.1)	1.20	0.25-5.71	NS	8(5.0)/3(6.5)	1.62	0.34-7.77	NS	6(7.4)/5(4.0)	0.50	0.13-1.93	NS	5(3.0)/6(14.0)	12.4	2.67-57.1	0.001
Cerad ≤1.5%	19(17.0)/19(20.7)	1.12	0.51-2.46	NS	31(19.1)/7(16.7)	0.92	0.34-2.50	NS	32(20.4)/6(12.8)	0.51	0.19-1.40	NS	17(20.2)/21(17.5)	0.95	0.43-2.08	NS	27(16.9)/11(25.0)	2.94	1.12-7.73	0.029
Cerad >1.5%	27(24.1)/20(21.7)	0.80	0.36-1.75	NS	37(22.8)/10(23.8)	1.05	0.40-2.78	NS	36(22.9)/11(23.4)	0.95	0.39-2.3	NS	18(21.4)/29(24.2)	1.18	0.54-2.62	NS	35(21.9)/12(27.3)	2.75	1.01-7.44	0.047
NFT	57(55.9)/38(52.1)	0.88	0.44-1.75	NS	77(55.4)/18(50.0)	0.85	0.37-2.0	NS	74(55.6)/21(50.0)	0.75	0.35-1.63	NS	34(50.0)/61(57.0)	1.35	0.67-2.72	NS	77(55.0)/18(51.4)	0.96	0.40-2.31	NS

*denotes the most common haplotype/homozygous genotype acting as the reference group in the analyses. Aff.(%) refers to number of individuals affected with SP/NFT.

USF1 − upstream transcription factor 1 gene, SNPs − single nucleotide polymorphisms, SP − senile plaques, NFT − neurofibrillary tangles, APOE4 − Apolipoprotein E ε4, OR − odds ratio, CI − confidence interval, *p* − p-value, NS − non significant p-value